This project aims to investigate determinants of women’s health and cancer outcomes by integrating multi-omics and phenotypic data from the UK Biobank. Women’s health spans endocrine disorders, gynecologic cancers, and psychosocial wellbeing, all of which are critical to quality of life and long-term survival. Yet the biological, lifestyle, and psychosocial factors that shape cancer prognosis and overall health remain incompletely understood.
Our central research questions are: (A)Which multi-omics biomarkers (genomic, transcriptomic, metabolomic) are associated with cancer prognosis and survival in women? (B)How do endocrine, lifestyle, and psychosocial factors interact with molecular features to influence health outcomes? (C)Can integrative multi-omics approaches improve prediction models for cancer outcomes and risk stratification?
The objectives of this study are: (A) To integrate genetic, molecular, lifestyle, and psychosocial data to identify determinants of cancer prognosis and women’s health outcomes. (B) To evaluate prognostic factors and predictive biomarkers that may aid early detection, risk stratification, and personalized management of gynecologic and other cancers. (C) To assess how lifestyle, reproductive history, and psychosocial wellbeing contribute to cancer progression, survivorship, and quality of life.
The rationale lies in the unique opportunity offered by UK Biobank: a large-scale, deeply phenotyped and genotyped cohort with long-term follow-up. By applying multi-omics integration and advanced analytical methods, this research will provide new insights into biological and social determinants of women’s health and cancer outcomes. Ultimately, it will inform public health strategies, support precision medicine for female cancers, and improve wellbeing across the female lifespan.
